Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells-Reference-Cited by-同舟云学术

Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells

Published:2023-11 Issue: Volume:77 Page:139-148
ISSN:1871-6784
Container-title:New Biotechnology
language:en
Short-container-title:New Biotechnology

Author:

Giang Kim Anh,Boxaspen Thorstein,Diao Yumei,Nilvebrant Johan,Kosugi-Kanaya Mizuha,Kanaya Minoru,Krokeide Silje Zandstra,Lehmann Fredrik,Svensson Gelius Stefan,Malmberg Karl-Johan,Nygren Per-Åke^ORCID

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Bioengineering,Biotechnology

Reference47 articles.

1. Bispecific antibodies in oncology;Esfandiari;Nat Rev Drug Discov,2022

2. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies;Tian;J Hematol Oncol,2021

3. Perspective: designing T-cell engagers with better therapeutic windows;Vafa;Front Oncol,2020

4. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities;Baeuerle;Curr Opin Oncol,2022

5. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment;Slaney;Cancer Discov,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation;Frontiers in Immunology;2024-08-08

2. A novel method to assess antibody-dependent cell-mediated cytotoxicity against influenza A virus M2 in immunized murine models;Biosafety and Health;2024-06

3. Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple Myeloma;2024-01-16